Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. - Wikidata - wikimedia - TriplyDB

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

http://www.wikidata.org/entity/Q40633414

about

Recent advances in understanding multiple myeloma Towards Stratified Medicine in Plasma Cell Myeloma The myeloma stem cell concept, revisited: from phenomenology to operational terms Advances in understanding prognosis in myeloma.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma Search for rare protein altering variants influencing susceptibility to multiple myeloma MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.Clinical value of molecular subtyping multiple myeloma using gene expression profiling Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B.Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.Monitoring multiple myeloma by quantification of recurrent mutations in serum.Logic programming reveals alteration of key transcription factors in multiple myeloma.Neutral tumor evolution in myeloma is associated with poor prognosis.Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.Utilizing next-generation sequencing in the management of multiple myeloma.Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.Immunologic approaches for the treatment of multiple myeloma.Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Current Review on High-Risk Multiple Myeloma.Clinical Trials in the Genomic Era.Mutational landscape reflects the biological continuum of plasma cell dyscrasias.RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.Diagnosis and classification of hematologic malignancies on the basis of genetics.

P2860

Q28070331-E93AAA61-DDC8-47B5-AFB0-6D28C969812F Q28074994-603E2891-1533-47E5-ACFB-B897EC72B12D Q28076070-7C34C225-9CC7-496B-890E-EEC81A4B3710 Q30244061-2047F912-EB71-45D1-BF77-EF2E909C93A9 Q31154933-65AFD97A-D472-4704-83AC-46C1D3A42FD1 Q33709470-8FC59FDE-16D9-469E-B227-26A712ACFD28 Q33829446-AC69B272-1A52-439D-8880-C0D47BD2F4A5 Q33869257-74DC46B0-E96B-4542-A340-17038E90CDC4 Q34556156-92191664-C7AD-40B8-9BA6-C3F4FB7C178D Q36511162-D60362A2-2CCD-4830-8049-D0CB82819DF1 Q36540781-70BDCB2B-EEB6-472E-9056-9F63D83E308F Q37037265-BB9758C2-F33B-4F53-9D90-6B5E86681075 Q37325007-CC3A80BE-EBC5-4536-B7DB-3675C736473D Q37443338-174B546A-9C78-4BDE-8CA9-A5BD36A63C55 Q37629738-520945F4-8370-43D8-85E4-05EE870BDE10 Q37662286-31F11216-7A01-4C2A-AD8D-40F70921E5D4 Q37697253-85A91CC7-61CC-4EA1-B941-9F6D25A3F42C Q37708798-8D1C6172-8CF5-4824-9A16-A9BEDE3BAF3E Q37744796-4E38399C-124A-41DC-9502-A7A4304BD902 Q38375161-CA31C03A-19FC-4427-A1A3-DDD277AAFF77 Q38611142-EE1EA56F-45C1-497E-8B78-E4CF337C58E3 Q38615431-F89B0D2F-2839-425A-A757-D96A7013CDCB Q38637046-27C63599-F29F-4573-A04B-12F1CF725F1D Q38645307-C318161D-CA0A-4403-8024-7774FADB3CAA Q38681814-C67E8832-2C9C-4DCF-A4DC-5EC35121DF84 Q38686915-4867A1C2-C4D4-433E-836B-EC7C41ADEEF3 Q38692244-80DB3719-E132-498E-B309-71BF8F8F5A10 Q38702294-AF47B03A-876F-428E-AECE-1F9E9F57244D Q38733973-6DDB1A69-F379-454C-B3B6-9CE82E228FE6 Q38742055-CEBEE4C3-7349-4594-8B3E-C3DC773E8985 Q38760679-37D8691F-1F20-44D1-B381-7AC8F3260AB4 Q38764731-63B78D25-F45A-4B7F-BA9F-88620CB793EB Q38852406-B22F4423-B5B1-4188-9047-453D0823AB1E Q38874675-47005FB6-8B92-49E8-91D1-A622CD5E1D77 Q38895167-230E1948-0FE5-4C72-8096-FD2E7DEDA968 Q38905607-8727BF82-3E18-4430-A861-D9D775722FD6 Q38943973-0CE21250-6335-46A6-95D1-483847B4E65D Q39137868-587EC72D-CAF6-4819-A23C-C227A401F9BC Q39261435-218D1D2E-65C9-4B4F-85BA-BCBC885FEE43 Q39363409-C34DA33C-A388-43E9-BAF7-4062ED76BEAF

P2860

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

http://www.wikidata.org/entity/Q40633414

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Mutational Spectrum, Copy Numb ...... With Newly Diagnosed Myeloma.

@en

Mutational Spectrum, Copy Numb ...... With Newly Diagnosed Myeloma.

@en-gb

type

label

Mutational Spectrum, Copy Numb ...... With Newly Diagnosed Myeloma.

@en

Mutational Spectrum, Copy Numb ...... With Newly Diagnosed Myeloma.

@en-gb

prefLabel

Mutational Spectrum, Copy Numb ...... With Newly Diagnosed Myeloma.

@en

Mutational Spectrum, Copy Numb ...... With Newly Diagnosed Myeloma.

@en-gb

P1154

Q40633414-33A4D997-6E48-4723-996F-31E073FF7BFE

P1433

Q40633414-9BB769F7-1E0A-415E-A7C1-0112D4EBB024

P1476

Q40633414-5F9C60A5-6DDD-4883-B0B7-A66F85653AB7

P2093

Q40633414-1AAA0CE1-39B5-4DDD-AA10-8BFB6641E038

Q40633414-21103B59-D082-4BB7-B9D6-829636492016

Q40633414-214A4326-EAE7-44D0-902A-E5307FC2B479

Q40633414-41687620-E065-496B-ADBE-E43A4547F936

Q40633414-50238DAB-F0F0-49AF-8254-F692EC3B95AA

Q40633414-76FC8674-AD2B-413F-B81C-893D8CE4867E

Q40633414-885F160C-6126-4A11-9FDE-86B2D28D84DF

Q40633414-89E1BD12-CEB4-480C-A99C-99F0771322C1

Q40633414-90C7F823-5F46-4CC6-885C-38E277492875

Q40633414-97F4DA36-039B-475B-9B72-48EFB0C8E42F

P304

Q40633414-C681E19C-B9E6-4AD1-97AC-EBB9C5543412

P31

Q40633414-3BF2E6A9-EBF8-420F-8C06-B0439F3BD232

P356

Q40633414-4B8FB066-C8B9-406B-AC03-95C0ABD57055

P407

Q40633414-A77BB4DC-13CF-4AF1-8FDC-E84DB29957B1

P433

Q40633414-1493526B-D3A3-4DA6-AA06-EDE282B00F1F

P478

Q40633414-11B8ACE2-8FB5-4F3A-A40B-56B24C1DE3B7

P50

Q40633414-1F744E57-9B93-4217-9F3D-D41F943A92C3

Q40633414-397CE024-3C1A-44F1-B061-7FDB903B5F34

Q40633414-641B9E31-5A1C-422F-A38C-E93EF4B7EE84

Q40633414-690566D6-AF52-4474-B010-595150C8C172

Q40633414-8629144A-3AAE-4875-8E47-9D40B9D5176C

Q40633414-BC631258-92F6-4D6D-B1BD-F476225D4A80

Q40633414-E3723C85-666C-4384-89A2-C55C061012DD

Q40633414-EAE26707-A579-43D7-A294-D3538D36FBAC

P5530

Q40633414-4A6F0C2D-C71F-49C9-8A7C-2A1D60CF8771

P577

Q40633414-5D96652E-2733-4FD5-BA72-6C706E96FC08

P6179

Q40633414-C94F1967-F216-4BA5-9836-5C1770C53C1B

P698

Q40633414-8BC6B133-74F8-4515-A18B-2AD6E731F2A5

P932

Q40633414-A3354217-6AB9-4935-A33C-4ED78310BFFC

P356

JCO.2014.59.1503

P1154

2-s2.0-84947116451

http://www.w3.org/2001/XMLSchema#string

P1433

Journal of Clinical Oncology

P1476

Mutational Spectrum, Copy Numb ...... s With Newly Diagnosed Myeloma

@en

P2093

Alex Murison

http://www.w3.org/2001/XMLSchema#string

Aneta Mikulasova

http://www.w3.org/2001/XMLSchema#string

David A Cairns

http://www.w3.org/2001/XMLSchema#string

David C Johnson

http://www.w3.org/2001/XMLSchema#string

Dil B Begum

http://www.w3.org/2001/XMLSchema#string

Fabio Mirabella

http://www.w3.org/2001/XMLSchema#string

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Graham H Jackson

http://www.w3.org/2001/XMLSchema#string

John R Jones

http://www.w3.org/2001/XMLSchema#string

Lauren I Aronson

http://www.w3.org/2001/XMLSchema#string

P304

3911-3920

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.59.1503

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Brian A. Walker

Christopher P Wardell

Gareth J Morgan

Annamaria Brioli

P5530

4408209

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005350338

http://www.w3.org/2001/XMLSchema#string

P698

26282654

http://www.w3.org/2001/XMLSchema#string

P932

6485456

http://www.w3.org/2001/XMLSchema#string